Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07924618). This is a study registration, not published results. Lead sponsor: Istanbul University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Type 2 Diabetes Mellitus, Obesity. Interventions: DRUG: Semaglutide; DRUG: Tirzepatide. Primary outcome measures: Change in Retinal Nerve Fiber Layer Thickness , Baseline to up to 18 months; Change in Retinal Thickness , Baseline to up to 18 months; Change in Superficial Retinal Vessel Density , Baseline to 18 months; Change in Deep Retinal Vessel Density , Baseline to 18 months; Change in Foveal Avascular Zone Area , Baseline to 18 months; Change in Choriocapillaris Flow Deficit Percentage , Baseline to 18 months. Brief summary: This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included. Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods. The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.